THE NEED FOR FEDERAL PREEMPTION OF STATE TORT CLAIMS IN THE CONTEXT OF "NEW DRUGS" AND PREMARKET-APPROVED MEDICAL DEVICES.Published in:2011By:Mottes, Lisa M.Publication type:Opinion
BASEBALL'S DNA TESTING POLICY STRIKES OUT: GENETIC DISCRIMINATION IN MAJOR LEAGUE BASEBALL.Published in:2011By:Stevens, Shannon K.Publication type:Opinion
REFORMING NEW JERSEY'S VACCINATION POLICY: THE CASE FOR THE CONSCIENTIOUS EXEMPTION BILL.Published in:2011By:Poreda, MichaelPublication type:Opinion
LOOKING INWARD: REGIONAL PARALLEL TRADE AS A MEANS OF BRINGING A AFFORDABLE DRUGS TO AFRICA.Published in:2011By:Buckley, MariannePublication type:Opinion
"ENDANGERMENT" OF THE COMMON LAW: DO RULE MAKINGS AS TO GREENHOUSE GASES UNDER THE CLEAN AIR ACT DISPLACE FEDERAL COMMON-LAW CLAIMS FOR THE PUBLIC NUISANCE OF GLOBAL WARMING?Published in:2011By:Grimm, Kyle G.Publication type:Opinion
Jacques Maritain's Embrace of Religious Pluralism and the Declaration on Religious Freedom.Published in:2011By:McCauliff, Catherine M. A.Publication type:Essay
Informed by the European Union Experience: What the United States Can Anticipate and Learn from the European Union's Regulatory Approach to Biosimilars.Published in:Seton Hall Law Review, 2011, v. 41, n. 2, p. 559By:Gitter, Donna M.Publication type:Article
Implementation of the Biosimilar Pathway: Economic and Policy Issues.Published in:Seton Hall Law Review, 2011, v. 41, n. 2, p. 511By:Grabowski, Heniy;Long, Genia;Mortimer, RichardPublication type:Article
Follow-On Biologics: Implementation Challenges and Opportunities.Published in:Seton Hall Law Review, 2011, v. 41, n. 2, p. 501By:Paradise, JordanPublication type:Article